格隆汇2月27日丨中国生物制药(01177.HK)宣布,集团与先为达生物签署独家战略合作协议。据此,集团与先为达生物就其研发的人白细胞介素-29(IL-29,也称干扰素λ1)项目(集团内部研发代号为CPX102)在中国、巴西、沙特阿拉伯、泰国、新加坡等19个国家达成独家许可与合作。CPX102是在IL-29的基础上,经蛋白质工程优化得到的雾化吸入溶液,属于III型干扰素的一种。目前集团正针对该项目...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.